Interestingly, 5–41% of HER2‐positive breast cancers present with regional heterogeneous HER2 amplification (Cottu et al., 2008; Ng et al., 2015), although this percentage depends on the applied definition. The gene discussed is ERBB2; the disease is breast carcinoma.